Fulltext

Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry

Wong YJ 1 , Kumar R 2 , Kumar R 1 , Tan J 1 , Liu CH 3 , Hui VK 4 Show all authors , Tan SS 5 , Kao JH 3 , Wong GH 4 , Thurairajah PH 6

Affiliations 

  • 1 Changi General Hospital, Changi, Singapore
  • 2 Duke-NUS Medicine Academic Clinical Program, Singhealth, Singapore
  • 3 National Taiwan University Hospital, Taipei, Taiwan
  • 4 Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong
  • 5 Selayang Hospital, Batu Caves, Selangor, Malaysia
  • 6 National University Hospital, Singapore
J Gastroenterol Hepatol, 2022 Aug;37(8):1642-1644.
PMID: 35723645 DOI: 10.1111/jgh.15918

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications